Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization in Combination With Immunotherapy and Targeted Therapy

NCT07065786 is registered in ClinicalTrials.gov with Zhongda Hospital as lead sponsor.

NCT NCT07065786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07065786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization in Combination With Immunotherapy and Targeted Therapy
Lead sponsor
Zhongda Hospital
Phase
Observational
Overall status
Active, not recruiting
Start date
January 1, 2024
Completion date
February 1, 2026
Enrollment
550 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

transcatheter arterial chemoembolization, unresectable hepatocellular carcinoma